Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL.

Cell. 2013 Dec 5;155(6):1309-22. doi: 10.1016/j.cell.2013.11.012.

PMID:
24315100
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603
[PubMed - indexed for MEDLINE]
3.

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B, Hager JH.

Cancer Discov. 2013 Sep;3(9):1020-9. doi: 10.1158/2159-8290.CD-13-0226. Epub 2013 Jun 18.

PMID:
23779130
[PubMed - indexed for MEDLINE]
4.

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.

Cancer Res. 2013 Jan 15;73(2):483-9. doi: 10.1158/0008-5472.CAN-12-3630. Epub 2012 Nov 1.

PMID:
23117885
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Resistance emerges to second-generation antiandrogens in prostate cancer.

Nelson WG, Yegnasubramanian S.

Cancer Discov. 2013 Sep;3(9):971-4. doi: 10.1158/2159-8290.CD-13-0405.

PMID:
24019330
[PubMed - indexed for MEDLINE]
6.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, Zhu P.

Cancer Discov. 2013 Sep;3(9):1030-43. doi: 10.1158/2159-8290.CD-13-0142. Epub 2013 Jul 10.

PMID:
23842682
[PubMed - indexed for MEDLINE]
7.

NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22.

PMID:
23699654
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

PMID:
23493310
[PubMed - indexed for MEDLINE]
Free Article
9.

Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.

Kim W, Ryan CJ.

Curr Treat Options Oncol. 2012 Jun;13(2):189-200. doi: 10.1007/s11864-012-0188-2. Review.

PMID:
22539224
[PubMed - indexed for MEDLINE]
10.

Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.

Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, Budunova I.

Cell Cycle. 2012 Jan 15;11(2):395-406. doi: 10.4161/cc.11.2.18945. Epub 2012 Jan 15.

PMID:
22223138
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer.

Menon MP, Higano CS.

Curr Oncol Rep. 2013 Apr;15(2):69-75. doi: 10.1007/s11912-013-0293-9.

PMID:
23341368
[PubMed - indexed for MEDLINE]
12.

Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.

Li H, Hassona MD, Lack NA, Axerio-Cilies P, Leblanc E, Tavassoli P, Kanaan N, Frewin K, Singh K, Adomat H, Böhm KJ, Prinz H, Guns ET, Rennie PS, Cherkasov A.

Mol Cancer Ther. 2013 Nov;12(11):2425-35. doi: 10.1158/1535-7163.MCT-13-0267. Epub 2013 Aug 12.

PMID:
23939374
[PubMed - indexed for MEDLINE]
13.

Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.

Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT Jr, Budunova I.

Cancer Res. 2008 Jun 15;68(12):4763-73. doi: 10.1158/0008-5472.CAN-07-6104.

PMID:
18559523
[PubMed - indexed for MEDLINE]
Free Article
14.

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.

Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ, Vander Griend DJ.

PLoS One. 2013;8(1):e53701. doi: 10.1371/journal.pone.0053701. Epub 2013 Jan 11.

PMID:
23326489
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.

PMID:
24101480
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Androgen receptor antagonists in castration-resistant prostate cancer.

Rathkopf D, Scher HI.

Cancer J. 2013 Jan-Feb;19(1):43-9. doi: 10.1097/PPO.0b013e318282635a. Review.

PMID:
23337756
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.

Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.

PMID:
19359544
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.

Hoffman-Censits J, Kelly WK.

Clin Cancer Res. 2013 Mar 15;19(6):1335-9. doi: 10.1158/1078-0432.CCR-12-2910. Epub 2013 Jan 8.

PMID:
23300275
[PubMed - indexed for MEDLINE]
Free Article
19.
20.

The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.

Lieberman R.

Am J Ther. 2013 Mar-Apr;20(2):128-31. doi: 10.1097/MJT.0b013e3182857f8e. No abstract available.

PMID:
23466618
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk